Prademagene zamikeracel (zevaskyn)
Prademagene zamikeracel is an FDA-licensed reference biologic from Abeona Therapeutics Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
zevaskyn Prademagene zamikeracel
Abeona Therapeutics Inc.
- Approved
- Apr 28, 2025
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Prademagene zamikeracel, in chronological order.
Reference approval
Approval date of the reference Prademagene zamikeracel product.
1 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for Prademagene zamikeracel (zevaskyn)?
No 351(k) biosimilars or interchangeable biosimilars referencing Prademagene zamikeracel are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.